166 related articles for article (PubMed ID: 15916433)
1. Design of small-sized libraries by combinatorial assembly of linkers and functional groups to a given scaffold: application to the structure-based optimization of a phosphodiesterase 4 inhibitor.
Krier M; Araújo-Júnior JX; Schmitt M; Duranton J; Justiano-Basaran H; Lugnier C; Bourguignon JJ; Rognan D
J Med Chem; 2005 Jun; 48(11):3816-22. PubMed ID: 15916433
[TBL] [Abstract][Full Text] [Related]
2. Molecular docking study and development of an empirical binding free energy model for phosphodiesterase 4 inhibitors.
Oliveira FG; Sant'Anna CM; Caffarena ER; Dardenne LE; Barreiro EJ
Bioorg Med Chem; 2006 Sep; 14(17):6001-11. PubMed ID: 16843671
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
Lee ME; Markowitz J; Lee JO; Lee H
FEBS Lett; 2002 Oct; 530(1-3):53-8. PubMed ID: 12387865
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
5. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
[TBL] [Abstract][Full Text] [Related]
6. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
7. Assessing the scaffold diversity of screening libraries.
Krier M; Bret G; Rognan D
J Chem Inf Model; 2006; 46(2):512-24. PubMed ID: 16562979
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro antiplatelet activity of new 4-(1-piperazinyl)coumarin derivatives. Human platelet phosphodiesterase 3 inhibitory properties of the two most effective compounds described and molecular modeling study on their interactions with phosphodiesterase 3A catalytic site.
Roma G; Di Braccio M; Grossi G; Piras D; Leoncini G; Bruzzese D; Signorello MG; Fossa P; Mosti L
J Med Chem; 2007 Jun; 50(12):2886-95. PubMed ID: 17500510
[TBL] [Abstract][Full Text] [Related]
9. Solid-phase synthesis and evaluation of libraries of substituted 4,5-dihydropyridazinones as vasodilator agents.
Gouault N; Martin-Chouly CA; Lugnier C; Cupif JF; Tonnelier A; Feger F; Lagente V; David M
J Pharm Pharmacol; 2004 Aug; 56(8):1029-37. PubMed ID: 15285848
[TBL] [Abstract][Full Text] [Related]
10. The application of a 3D-QSAR (autoMEP/PLS) approach as an efficient pharmacodynamic-driven filtering method for small-sized virtual library: application to a lead optimization of a human A3 adenosine receptor antagonist.
Moro S; Bacilieri M; Cacciari B; Bolcato C; Cusan C; Pastorin G; Klotz KN; Spalluto G
Bioorg Med Chem; 2006 Jul; 14(14):4923-32. PubMed ID: 16564691
[TBL] [Abstract][Full Text] [Related]
11. Searching for a reliable orientation of ligands in their binding site: comparison between a structure-based (Glide) and a ligand-based (FIGO) approach in the case study of PDE4 inhibitors.
Gratteri P; Bonaccini C; Melani F
J Med Chem; 2005 Mar; 48(5):1657-65. PubMed ID: 15743207
[TBL] [Abstract][Full Text] [Related]
12. Concept of combinatorial de novo design of drug-like molecules by particle swarm optimization.
Hartenfeller M; Proschak E; Schüller A; Schneider G
Chem Biol Drug Des; 2008 Jul; 72(1):16-26. PubMed ID: 18564216
[TBL] [Abstract][Full Text] [Related]
13. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Aug; 12(15):4089-100. PubMed ID: 15246087
[TBL] [Abstract][Full Text] [Related]
14. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
Card GL; Blasdel L; England BP; Zhang C; Suzuki Y; Gillette S; Fong D; Ibrahim PN; Artis DR; Bollag G; Milburn MV; Kim SH; Schlessinger J; Zhang KY
Nat Biotechnol; 2005 Feb; 23(2):201-7. PubMed ID: 15685167
[TBL] [Abstract][Full Text] [Related]
15. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
17. Focused combinatorial library design based on structural diversity, druglikeness and binding affinity score.
Chen G; Zheng S; Luo X; Shen J; Zhu W; Liu H; Gui C; Zhang J; Zheng M; Puah CM; Chen K; Jiang H
J Comb Chem; 2005; 7(3):398-406. PubMed ID: 15877468
[TBL] [Abstract][Full Text] [Related]
18. Scaffold diversity of natural products: inspiration for combinatorial library design.
Grabowski K; Baringhaus KH; Schneider G
Nat Prod Rep; 2008 Oct; 25(5):892-904. PubMed ID: 18820757
[TBL] [Abstract][Full Text] [Related]
19. A screening study of ChirBase molecular database to explore the expanded chiral pool derived from the application of chiral chromatography.
Piras P; Roussel C
J Pharm Biomed Anal; 2008 Apr; 46(5):839-47. PubMed ID: 17942261
[TBL] [Abstract][Full Text] [Related]
20. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
